NeuroPace Inc unveils NAUTILUS Study results at AAN Annual Meeting

NeuroPace Inc unveils NAUTILUS Study results at AAN Annual Meeting
NeuroPace Inc reveals NAUTILUS data

NeuroPace Inc is set to present new findings from the NAUTILUS Study, the first and only randomized trial of neuromodulation for drug-resistant idiopathic generalized epilepsy (IGE), at the 2026 AAN Annual Meeting.

The presentation, led by Dr. Martha Morrell, will provide the latest insights into this key research advancement. Those unable to attend in person are encouraged to watch the event online to stay informed on the evolving landscape of neuromodulation therapy for challenging epilepsy cases.

NeuroPace previously released NAUTILUS Study results, highlighting advances in neuromodulation for drug-resistant IGE at the 2026 AAN meeting. The company has also encouraged epilepsy patients with uncontrolled seizures to assess their suitability for the RNS System through an online quiz. Both initiatives reflect ongoing efforts to expand treatment options for challenging epilepsy cases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.